<DOC>
	<DOCNO>NCT02652520</DOCNO>
	<brief_summary>Kidney transplantation treatment choice end stage renal disease , increase life expectancy quality life . Improvement organ preservation critical issue context . This safety study evaluate use oxygen carrier HEMO2Life® additive organ preservation solution kidney transplantation .</brief_summary>
	<brief_title>Evaluation Marine OXYgen Carrier : HEMO2Life® hypOthermic Kidney Graft Preservation , Before Transplantation ( OXYOP )</brief_title>
	<detailed_description>Security use HEMO2Life® analyze collect event within first 3 month term : 1 . HEMO2Life® adverse effect 2. graft safety 3. recipient safety ( adverse event ) Accountability search achieve event .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>For Kidney : The first ten local kidney participate center meet exclusion criterion . Graft retrieve adult donor Graft decease donor brain death ( DBD ) Graft locally transplant one 6 kidney transplant center participate study Graft store preservation solution contain HEMO2Life® For Patient : Patient sign inform consent form In case patient unable sign inform consent form patient judicial protection ( supervision , guardianship ) inform consent form obtain patient supervisor/guardianshiper/parents , sign together patient inform consent form . The probability inclusion patient unable sign inform consent form low ca n't know receiver condition graft . Patient &gt; 18 year old Graft living donor Graft donor cardiovascular death ( DCD ) Graft dedicate multiorgan transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>Organ preservation</keyword>
</DOC>